Progressive B-cell chronic lymphocytic leukemia (B-CLL) is often complicated by autoimmune hemolytic anemia (AIHA), which in some cases may be refractory to conventional therapy such as corticosteroids, rituximab and splenectomy. We report here on 5 patients (median age 66 years, range 59-69) with advanced B-CLL, all of whom developed severe transfusiondependent AIHA resistant to conventional therapy and received subcutaneous (SC) or intravenous (IV) alemtuzumab, a humanized monoclonal antibody that targets the CD52 antigen as salvage treatment for AIHA. Alemtuzumab was well tolerated with only minor 'first dose' reactions. All 5 patients responded with a X2.0 g/dl rise in hemoglobin (Hb) concentration, in the absence of further transfusions, after a median time of 5 weeks (range 4-7), and the mean Hb increased from 7.2 g/dl at baseline to 11.9 g/dl at end of treatment. All patients remained stable, without further AIHA episodes, after a median follow-up time of 12 months with a mean Hb of 12.5 g/dl (range 12.2-12.9). For patients with severe, refractory CLL-related AIHA, who have not previously responded to conventional therapy, alemtuzumab is an effective agent.
Introduction
Autoimmunity sometimes occurs in patients with B-cell chronic lymphocytic leukemia (B-CLL) and presents as autoimmune hemolytic anemia (AIHA), immune thrombocytopenia or pure red-cell aplasia (PRCA). 1 AIHA is the most common autoimmune disorder associated with B-CLL, and about 5% of patients with B-CLL experience AIHA. 2 Chemotherapeutic agents such as alkylating agents and purine analogs, often used in the treatment of B-CLL, are considered risk factors for the development of AIHA; [3] [4] [5] however, recent data indicate that the addition of cyclophosphamide to fludarabine may reduce the risk of AIHA (Catovsky et al., Blood 2004; abstr 140). Although the exact mechanism of autoimmunity remains unclear, it is thought that the imbalance between subsets of T cells, which is further aggravated by therapy, may contribute to the development of AIHA. 6, 7 Initial treatment for AIHA in patients with B-CLL usually includes corticosteroids, followed by cytotoxic drugs, intravenous (i.v.) immunoglobulins, splenectomy and even cyclosporine in unresponsive patients. 1 Although patients with both B-CLL and AIHA may initially respond to these treatments, relapses are common and some patients become refractory; 2 therefore, additional therapeutic options are needed for the treatment of AIHA. Recently, monoclonal antibodies have emerged as an important therapeutic option for AIHA in patients with B-CLL, and rituximab (anti-CD20) is now part of the standard therapy for AIHA. 8 Alemtuzumab, a monoclonal antibody to the CD52 antigen, has demonstrated efficacy in the treatment of B-CLL, [9] [10] [11] [12] and owing to its prominent immunosuppressive effects, 13 may also be suitable for therapy of autoimmune complications as well. We have recently reported the effect of alemtuzumab in one patient with CLL-related AIHA.
14 In this paper, we report on the effect of alemtuzumab treatment which was refractory to several lines of conventional therapy, in an additional five patients with B-CLL and severe AIHA.
Patients and methods

Patients
Five male patients with advanced B-CLL, who had developed severe direct antiglobulin test (DAT)-positive AIHA resistant to various conventional therapies, such as corticosteroids, chemotherapy or rituximab (see Results), were treated with alemtuzumab and included in this analysis.
Treatment schedule
On day 1, alemtuzumab 3 or 10 mg was administered by a subcutaneous (s.c.) injection in the thigh or as an i.v. infusion, and then dose escalated to 30 mg, if well tolerated at lower doses. The 30 mg dose was administered three times weekly (tiw) for a maximum of 12 weeks. To prevent 'first-dose' reactions, patients received paracetamol and antihistamines, such as clemastine, 30 min before injection. Allopurinol 300 mg/day was given during the first 4 weeks of treatment. For antiinfective prophylaxis, valacyclovir (250 mg tablets, twice daily) and cotrimoxazole (once or twice daily, tiw) were administered during treatment, and for 8 weeks following end of treatment.
Patient monitoring
Before treatment, patients underwent a full blood count, biochemical screen and DAT. During treatment, blood counts and a differential were analysed at least once a week. If a patient had a hemoglobin (Hb) count p8 g/dl, then red blood cell transfusions were given.
Response criteria
AIHA response was defined as the elimination of the need for red blood cell transfusions and a X2.0 g/dl rise in Hb concentration independent of transfusions. CLL response to treatment was defined by National Cancer Institute (NCI) criteria. 15 
Results
Patient characteristics
Patient clinical characteristics are shown in Table 1 . The median age was 66 years (range, 59-69 years), and the time since B-CLL diagnosis ranged from 16 to 132 months. Previous treatments for B-CLL included chlorambucil, fludarabine þ cyclophosphamide with or without rituximab, chlorambucil þ prednisone and cyclophosphamide þ vincristine þ prednisone (CVP). Previous treatment for AIHA included prednisone, i.v. immunoglobulin, CVP, cyclosporine A and rituximab. The mean Hb concentration at baseline was 7.2 g/dl (range 4.5-10.4) and all patients had received red blood cell transfusions owing to AIHA. In patient no. 5, a bone marrow examination revealed a modest chemotherapy induced suppression of erythropoiesis that may have contributed partially to the anemia present at baseline, but there were no signs of PRCA.
Treatment and toxicity
The alemtuzumab dose was quickly escalated to 30 mg tiw s.c. (patients no. 1, 2 and 5) or i.v. (patients no. 3 and 4) and continued for a median of 5 weeks (range, 3-12 weeks). Alemtuzumab was well tolerated in all patients. Mild first-day reactions, mainly grade 1 fever and rigour, occurred in three patients (patients no. 1, 2 and 4). Patient no. 2 had a cytomegalovirus reactivation with fever after 3 weeks of therapy, but responded rapidly to foscarnet. Alemtuzumab was withdrawn at this timepoint as Hb had increased. Patient no. 3 developed Escherchia coli septicemia (not neutropenic) after 2 weeks of therapy, which resolved after treatment with antibiotics. Alemtuzumab was temporarily withheld for 2.5 weeks in this patient. After 12 weeks of alemtuzumab treatment, patient no. 1 had transient gastroenteritis. Transient grade 4 neutropenia occurred in two patients (no. 1 and 4) after 1 and 5 weeks of alemtuzumab treatment, respectively. The neutropenia resolved spontaneously in patient no. 4, but patient no. 1 required treatment with pegfilgrastim.
AIHA response
The AIHA response to treatment with alemtuzumab is shown in Table 2 and Figure 1 . At the start of alemtuzumab treatment, all 5 patients had severe, transfusion-dependent DAT-positive AIHA with a mean Hb of 7.2 g/dl (range 4.5-10.4 g/dl). All patients responded with a X2.0 g/dl rise in Hb concentration and elimination of the need for transfusion after a median of 5 weeks (range, 4-7 weeks; Table 2 ). At the end of therapy, mean Hb concentration was 11.9 g/dl (range, 9.0-14.2 g/dl; Figure 1 ). All patients were clinically stable with no further 
Clinical CLL response
Clinical CLL responses (as defined by NCI criteria) were seen in 3 patients. Two patients achieved a complete response (CR; patients no. 3 and 4), one patient achieved a partial response (PR; patient 1), and one patient had stable disease (patient 2). Patient no. 5 is still on therapy and is not yet evaluable for response.
Discussion
AIHA is a frequent and serious complication in patients with B-CLL. 2 The majority of patients respond well to conventional immunosuppressive therapy with or without splenectomy; however, some fail to respond and may develop life-threatening anemia.
Recently, monoclonal antibodies such as rituximab have been introduced to treat patients with nonCLL-related autoimmune cytopenias, with efficacy reported in approximately 75% of patients. 16 Another study reported that three of four patients with both B-CLL and AIHA responded to rituximab. 17 Rituximab, in combination with cyclophosphamide and dexamethasone, resulted in remission of AIHA in patients with both B-CLL and refractory AIHA. 18 Alemtuzumab, a monoclonal antibody directed against the CD52 antigen, has also been reported to be effective in patients with nonCLL-related autoimmune cytopenias. [19] [20] [21] [22] Alemtuzumab has also shown antitumour activity against B-CLL, with a response rate of 30-40% in patients with advanced B-CLL, who were previously treated with alkylating agents and had failed fludarabine therapy 9, 12 This antitumor activity, in combination with its profound immunosuppressive activity, 13 merits investigation in patients with severe CLL-related AIHA as well. We have recently reported on one patient with CLL and AIHA, who had life-threatening AIHA. This patient responded dramatically to alemtuzumab, with resolution of AIHA, and is still in remission after 31 months of follow-up, without further episodes of AIHA.
14 Another case report described the results of alemtuzumab treatment in a patient with B-CLL and PRCA: following treatment with alemtuzumab, the patient achieved a CR with resolution of PRCA. 23 To confirm and extend our observation beyond a single patient, 14 we report here on an additional five patients with Treatment of AIHA with alemtuzumab C Karlsson et al B-CLL and AIHA, who were treated with alemtuzumab. All had received but failed several lines of conventional therapies for AIHA. However, only two of the patients had received before rituximab earlier for AIHA; the reason for using alemtuzumab before, instead of rituximab was AIHA in combination with progressive CLL. All five patients responded to treatment with alemtuzumab, with elimination of AIHA and a marked increase in hemoglobin concentrations. In parallel, CLL responses were achieved in all but one patient. Therefore, results from this report suggest that alemtuzumab may be highly effective in the treatment of severe, resistant AIHA in patients with B-CLL who have failed to respond to conventional immunosuppressive therapy, splenectomy and/or chemotherapy. Alemtuzumab may be considered even before rituximab if AIHA is accompanied by progressive CLL in need of cytoreductive therapy. As such, this agent appears to be an important therapeutic tool, especially for patients with life-threatening AIHA. Further studies are warranted on early use of alemtuzumab in CLL-related AIHA and immune thrombocytopenia, with the aim of avoiding splenectomy and other therapeutic alternatives that lack anti-CLL activity.
